News | August 4, 2020

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection London, UK, and Research Triangle Park, NC, August 4, 2020 – ReViral Ltd., a clinical-stage biopharmaceutical company focused on...